SEC Form 4 · accession 0001209191-16-156552
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Wiezorek
Officer — SVP Clinical Development
Period of report
Dec 20, 2016
Accepted (ET)
Dec 22, 2016 · 4:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 20, 2016 | S | 716 | $50.86 | D | 15,095 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.